Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

doi:10.4252/wjsc.v9.i3.45

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12186)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

588

WORD

372

HTML

6709

Figures (1-6)

271

Sum=7940

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

858

Download

1419

Sum=2277

Publishing Process of This Article

Item

Count

Browse

1052

Download

917

Sum=1969

Mar 26, 2017 (publication date) through Sep 19, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Mar 26, 2017; 9(3): 45-67
Published online Mar 26, 2017. doi: 10.4252/wjsc.v9.i3.45

Full Size Figure Download Figure

Figure 4 IMT504 treatment induced a marked recovery of the diabetic condition in streptozotocin-treated rats. Arrows indicate IMT504 treatment, which consisted of daily subcutaneous injections containing 4 mg of IMT504 over 10 successive days. Experimental details are described in Bianchi et al[357]. STZ: Streptozotocin.

Citation: Zorzopulos J, Opal SM, Hernando-Insúa A, Rodriguez JM, Elías F, Fló J, López RA, Chasseing NA, Lux-Lantos VA, Coronel MF, Franco R, Montaner AD, Horn DL. Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy. World J Stem Cells 2017; 9(3): 45-67
URL: https://www.wjgnet.com/1948-0210/full/v9/i3/45.htm
DOI: https://dx.doi.org/10.4252/wjsc.v9.i3.45